SOPH Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 8.25
- P/S (TTM)
- 4.65
- EV/EBITDA
- -0.30
Profitability & growth
- ROE (TTM)
- -123.3%
- Operating margin
- -79.7%
- Revenue growth YoY
- 22.0%
- Dividend yield
- —
- Beta
- 0.98
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Sophia Genetics SA
Company profileSophia Genetics SA (SOPH) is a leading innovator in data-driven medicine, specializing in advanced genomic and clinical data analytics aimed at improving patient outcomes. By leveraging state-of-the-art machine learning technologies, the company offers an integrated platform that empowers healthcare providers to decipher intricate genomic data, thereby enabling personalized treatment approaches in areas such as oncology, rare diseases, and hereditary conditions. With a strong global presence and strategic collaborations with key healthcare organizations, Sophia Genetics is poised to reshape…
Classification
- Sector
- Healthcare
- Industry
- Health Information Services
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- LA PIECE 12, ROLLE, SWITZERLAND
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer